Heparin
- Generic Name
- Heparin
- Brand Names
- Heparin Leo
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- T2410KM04A
- Background
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (fac...
- Indication
Unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension, prevention of post-operative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery. In cardiology, it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin ther...
- Associated Conditions
- Blunt Injury, Clotting, Coagulopathy, Consumption, Contusions, Deep vein thrombosis postoperative, Disseminated Intravascular Coagulation (DIC), External Hemorrhoid, Inflammation, Inflammatory, non-infectious pruritic dermatosis, Interstitial Cystitis, Post procedural pulmonary embolism, Pulmonary Embolism, ST Segment Elevation Myocardial Infarction (STEMI), Sprains, Thromboembolism, Unstable Angina Pectoris, Venous Thrombosis (Disorder), Hematomas, Peripheral arterial embolism, Thromboembolic phenomena, Varicosities of the great saphenous vein
- Associated Therapies
- Circulation, Extracorporeal, Dialysis therapy, Transfusions, Maintenance of patency of IV injection devices
Patients Preference With Self-Injection: The PRISM Study
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2009-03-10
- Lead Sponsor
- Hamilton Health Sciences Corporation
- Target Recruit Count
- 100
- Registration Number
- NCT00253396
- Locations
- 🇨🇦
St. Joseph's Healthcare, Hamilton, Ontario, Canada
Does Thinning the Blood During Surgery Prevent Blood Clots Following Total Knee Replacement Surgery
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2012-04-17
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00253851
- Locations
- 🇨🇦
Ottawa Hospital, Ottawa, Ontario, Canada
Risk of Developing Antibodies to Heparin-PF4 After Heart Surgery
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2013-02-25
- Lead Sponsor
- Duke University
- Target Recruit Count
- 1015
- Registration Number
- NCT00237328
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Rochester, Minnesota, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸University of North Carolina, Chapel Hill, North Carolina, United States
Impact of Heparin on the Need for Mechanical Ventilation in Neonates
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2007-10-23
- Lead Sponsor
- University Medicine Greifswald
- Target Recruit Count
- 270
- Registration Number
- NCT00196469
- Locations
- 🇩🇪
University Hospital Department of Pediatrics/Institute for Immunology and Transfusion Medicine, Greifswald, Germany
PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2011-01-10
- Lead Sponsor
- McMaster University
- Target Recruit Count
- 3659
- Registration Number
- NCT00182143
- Locations
- 🇨🇦
Kingston General Hospital, Kingston, Ontario, Canada
🇨🇦Sunnybrook and Women's College Health Science Centre, Toronto, Ontario, Canada
🇨🇦St Michaels Hospital, Toronto, Ontario, Canada
The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention
- Conditions
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2008-07-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 947
- Registration Number
- NCT00133731
- Locations
- 🇺🇸
Los Angeles Cardiology Associates, Los Angeles, California, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸The Cleveland Clinic Foundation, Cleveland, Ohio, United States
Heparin or Enoxaparin in Patients With Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-07-26
- Last Posted Date
- 2011-02-21
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 6
- Registration Number
- NCT00004875
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Chicago (Lakeside), Chicago, Illinois, United States
🇺🇸Evanston Northwestern Health Care, Evanston, Illinois, United States
Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)
- Conditions
- Interventions
- First Posted Date
- 2004-03-11
- Last Posted Date
- 2012-01-05
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 150
- Registration Number
- NCT00079586
- Locations
- 🇺🇸
The Cleveland Clinic, Cleveland, Ohio, United States
Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB
- Conditions
- Interventions
- First Posted Date
- 2003-11-27
- Last Posted Date
- 2011-11-10
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 150
- Registration Number
- NCT00073593
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)
- Conditions
- First Posted Date
- 2003-08-13
- Last Posted Date
- 2011-04-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1452
- Registration Number
- NCT00067093
- Locations
- 🇺🇸
Lehigh Valley Hospital, Allentown, Pennsylvania, United States
🇺🇸MIMA Century Research Associates, Melbourne, Florida, United States
🇺🇸Jackson Cardio-Vascular Clinic, Jacksonville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.